JP2019534315A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019534315A5 JP2019534315A5 JP2019526565A JP2019526565A JP2019534315A5 JP 2019534315 A5 JP2019534315 A5 JP 2019534315A5 JP 2019526565 A JP2019526565 A JP 2019526565A JP 2019526565 A JP2019526565 A JP 2019526565A JP 2019534315 A5 JP2019534315 A5 JP 2019534315A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical
- patient
- preparation according
- present
- pharmaceutical preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 50
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 32
- 238000010521 absorption reaction Methods 0.000 claims description 21
- 239000003623 enhancer Substances 0.000 claims description 21
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 20
- NLEBIOOXCVAHBD-QKMCSOCLSA-N dodecyl beta-D-maltoside Chemical compound O[C@@H]1[C@@H](O)[C@H](OCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 NLEBIOOXCVAHBD-QKMCSOCLSA-N 0.000 claims description 19
- 208000012488 Opiate Overdose Diseases 0.000 claims description 18
- 208000024891 symptom Diseases 0.000 claims description 17
- 239000011780 sodium chloride Substances 0.000 claims description 16
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 15
- GYWMRGWFQPSQLK-OPHZJPRHSA-N (4r,4as,7as,12bs)-3-(cyclopropylmethyl)-7-methylidene-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,9-diol;hydron;chloride Chemical compound Cl.N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 GYWMRGWFQPSQLK-OPHZJPRHSA-N 0.000 claims description 14
- 229960000677 nalmefene hydrochloride Drugs 0.000 claims description 14
- 239000002253 acid Substances 0.000 claims description 12
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 12
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 12
- 239000007864 aqueous solution Substances 0.000 claims description 11
- 239000003381 stabilizer Substances 0.000 claims description 11
- 239000007951 isotonicity adjuster Substances 0.000 claims description 10
- WJBLNOPPDWQMCH-MBPVOVBZSA-N Nalmefene Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 WJBLNOPPDWQMCH-MBPVOVBZSA-N 0.000 claims description 3
- 229960005297 nalmefene Drugs 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims 3
- 229940124532 absorption promoter Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 39
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 26
- 238000000034 method Methods 0.000 description 15
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 9
- 206010038678 Respiratory depression Diseases 0.000 description 9
- -1 alkyl saccharide Chemical class 0.000 description 8
- 239000003401 opiate antagonist Substances 0.000 description 4
- 210000003928 nasal cavity Anatomy 0.000 description 3
- 210000001989 nasopharynx Anatomy 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 239000003833 bile salt Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 230000003533 narcotic effect Effects 0.000 description 2
- 229940005483 opioid analgesics Drugs 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 208000022540 Consciousness disease Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010027646 Miosis Diseases 0.000 description 1
- 208000007379 Muscle Hypotonia Diseases 0.000 description 1
- 206010035669 Pneumonia aspiration Diseases 0.000 description 1
- 206010038669 Respiratory arrest Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010069351 acute lung injury Diseases 0.000 description 1
- 208000008784 apnea Diseases 0.000 description 1
- 201000009807 aspiration pneumonia Diseases 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 208000018875 hypoxemia Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000003547 miosis Effects 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023112864A JP7730443B2 (ja) | 2016-11-18 | 2023-07-10 | オピオイド過剰摂取を処置するための組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662424378P | 2016-11-18 | 2016-11-18 | |
| US62/424,378 | 2016-11-18 | ||
| PCT/US2017/060964 WO2018093666A1 (en) | 2016-11-18 | 2017-11-09 | Compositions and methods for the treatment of opioid overdose |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023112864A Division JP7730443B2 (ja) | 2016-11-18 | 2023-07-10 | オピオイド過剰摂取を処置するための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019534315A JP2019534315A (ja) | 2019-11-28 |
| JP2019534315A5 true JP2019534315A5 (https=) | 2020-12-17 |
| JP7312698B2 JP7312698B2 (ja) | 2023-07-21 |
Family
ID=62146061
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019526565A Active JP7312698B2 (ja) | 2016-11-18 | 2017-11-09 | オピオイド過剰摂取を処置するための組成物および方法 |
| JP2023112864A Active JP7730443B2 (ja) | 2016-11-18 | 2023-07-10 | オピオイド過剰摂取を処置するための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023112864A Active JP7730443B2 (ja) | 2016-11-18 | 2023-07-10 | オピオイド過剰摂取を処置するための組成物および方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US11458091B2 (https=) |
| EP (1) | EP3541386A4 (https=) |
| JP (2) | JP7312698B2 (https=) |
| CN (1) | CN110139651A (https=) |
| AU (2) | AU2017360910B2 (https=) |
| CA (1) | CA3044221A1 (https=) |
| IL (2) | IL266674B2 (https=) |
| RU (1) | RU2769397C2 (https=) |
| WO (1) | WO2018093666A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9895444B2 (en) | 2004-08-25 | 2018-02-20 | Aegis Therapeutics, Llc | Compositions for drug administration |
| CN110139651A (zh) | 2016-11-18 | 2019-08-16 | 欧邦特制药公司 | 用于治疗阿片样物质过量的组合物和方法 |
| WO2019157099A1 (en) | 2018-02-06 | 2019-08-15 | Aegis Therapeutics, Llc | Intranasal epinephrine formulations and methods for the treatment of disease |
| CA3100834A1 (en) * | 2018-05-17 | 2019-11-21 | Aegis Therapeutics Llc | Formulations and methods for the prevention of opioid overdose |
| WO2019231993A1 (en) * | 2018-06-01 | 2019-12-05 | Purdue Pharma L.P. | Compositions and methods for opioid overdose rescue |
| EP3876938A4 (en) | 2018-11-06 | 2022-08-10 | Purdue Pharma L.P. | COMPOSITIONS AND METHODS OF ADMINISTRATION OF OPIOID ANTAGONISTS |
| CA3119031A1 (en) * | 2018-11-07 | 2020-05-14 | Opiant Pharmaceuticals, Inc. | Methods, parenteral pharmaceutical formulations, and devices for the prevention of opioid overdose |
| EP3946547B1 (en) | 2019-03-26 | 2026-03-25 | Pinova Therapeutics Inc. | Devices and methods for delivering pharmaceutical compositions |
| US10653690B1 (en) * | 2019-07-09 | 2020-05-19 | Orexo Ab | Pharmaceutical composition for nasal delivery |
| US10729687B1 (en) | 2019-07-09 | 2020-08-04 | Orexo Ab | Pharmaceutical composition for nasal delivery |
| WO2021159077A1 (en) * | 2020-02-07 | 2021-08-12 | Case Western Reserve University | Compositions and methods for attenuating opioid induced cardio and/or respiratory depression |
| US20230256099A1 (en) * | 2020-05-04 | 2023-08-17 | Amphastar Pharmaceuticals, Inc. | Safe Use of Bile Acids and Their Salts as Enhancers for Nasal Delivery of Pharmaceuticals |
| RS63725B1 (sr) | 2020-05-18 | 2022-12-30 | Orexo Ab | Nova farmaceutska kompozicija za davanje leka |
| US20220111162A1 (en) * | 2020-07-29 | 2022-04-14 | Lido Ventures Llc | Apparatus, system, and method for facilitating intranasal treatment of a patient |
| MX2023009055A (es) * | 2021-02-01 | 2024-01-05 | Clear Scient Inc | Compuestos de secuestro para el tratamiento de un trastorno por uso de sustancias y usos de los mismos. |
| US20220387407A1 (en) * | 2021-02-08 | 2022-12-08 | Case Western Reserve University | Compositions and methods for attenuating opioid induced cardio and/or respiratory depression |
| US11278709B1 (en) | 2021-03-12 | 2022-03-22 | Pocket Naloxone Corp. | Drug delivery device and methods for using same |
| AU2022323269A1 (en) * | 2021-08-04 | 2024-02-29 | Indivior Inc. | Compositions and methods for the treatment of opioid overdose |
| GB202117016D0 (en) | 2021-11-25 | 2022-01-12 | Orexo Ab | New pharmaceutical device |
| AR127780A1 (es) | 2021-11-25 | 2024-02-28 | Orexo Ab | Nueva composición farmacéutica que comprende adrenalina |
| JP2025521774A (ja) * | 2022-07-05 | 2025-07-10 | ジー２ジーバイオ インコーポレイテッド | セマグルチドまたはその薬学的に許容可能な塩を含む徐放性微粒球製剤およびその製造方法 |
| WO2024222920A1 (zh) * | 2023-04-28 | 2024-10-31 | 成都苑东生物制药股份有限公司 | 一种用于鼻内给药的药物制剂及其制备方法 |
| WO2025255416A1 (en) * | 2024-06-05 | 2025-12-11 | TMTRx, Inc. | Fentanyl and fentanyl analogue overdose reversal |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4464378A (en) | 1981-04-28 | 1984-08-07 | University Of Kentucky Research Foundation | Method of administering narcotic antagonists and analgesics and novel dosage forms containing same |
| US4987136A (en) | 1982-03-16 | 1991-01-22 | The Rockefeller University | Method for controlling gastrointestinal dysmotility |
| US4882335A (en) | 1988-06-13 | 1989-11-21 | Alko Limited | Method for treating alcohol-drinking response |
| US4880813A (en) | 1988-07-22 | 1989-11-14 | Baker Cummins Pharmaceuticals, Inc. | Method of treatment for allergic rhinitis |
| US5069895A (en) | 1989-11-09 | 1991-12-03 | Diamond Ivan F | Methods for the treatment of alcohol intoxication and dependence |
| US5369095A (en) | 1990-02-14 | 1994-11-29 | Alcon Laboratories, Inc. | Compositions and method comprising substituted glycosides as mucus membrane permeation enhancers |
| IL97075A0 (en) | 1990-02-14 | 1992-03-29 | Alcon Lab Inc | Topical pharmaceutical composition containing an alkyl saccharide |
| US6271240B1 (en) * | 1996-05-06 | 2001-08-07 | David Lew Simon | Methods for improved regulation of endogenous dopamine in prolonged treatment of opioid addicted individuals |
| RU2004107501A (ru) | 2001-08-14 | 2005-02-20 | Байотай Терапис Корпорейшн (Fi) | Способ лечения алкоголизма или злоупотребления алкоголем |
| US20140162965A1 (en) | 2004-08-25 | 2014-06-12 | Aegis Therapeutics, Inc. | Compositions for oral drug administration |
| US9114069B2 (en) | 2004-08-25 | 2015-08-25 | Aegis Therapeutics, Llc | Antibacterial compositions for drug administration |
| US8268791B2 (en) * | 2004-08-25 | 2012-09-18 | Aegis Therapeutics, Llc. | Alkylglycoside compositions for drug administration |
| US9895444B2 (en) | 2004-08-25 | 2018-02-20 | Aegis Therapeutics, Llc | Compositions for drug administration |
| WO2006025882A2 (en) | 2004-08-25 | 2006-03-09 | The Uab Research Foundation | Absorption enhancers for drug administration |
| US20110257096A1 (en) | 2004-08-25 | 2011-10-20 | Aegis Therapeutics, Inc. | Compositions for drug administration |
| CN1305474C (zh) * | 2004-10-13 | 2007-03-21 | 北京国药龙立生物医药新技术有限公司 | 盐酸纳美芬鼻腔给药制剂 |
| US20070212307A1 (en) | 2006-02-10 | 2007-09-13 | Daniel Wermeling | Pharmaceutical Compositions Comprising an Opioid Receptor Antagonist and Methods of Using Same |
| US20080090771A1 (en) | 2006-10-06 | 2008-04-17 | Shire Llc | Abuse-resistant hydrocodone compounds, compositions and methods of using the same |
| CA2677205A1 (en) | 2007-01-31 | 2008-08-07 | University Of Virginia Patent Foundation | Topiramate plus naltrexone for the treatment of addictive disorders |
| IL187159A0 (en) | 2007-07-03 | 2009-02-11 | Gur Megiddo | Use of metadoxine in relief of alcohol intoxication |
| WO2009029308A1 (en) | 2007-08-27 | 2009-03-05 | University Of Virginia Patent Foundation | Medication combinations for the treatment of alcoholism and drug addiction |
| CA2756690C (en) | 2008-03-28 | 2016-08-16 | Hale Biopharma Ventures, Llc | Administration of benzodiazepine compositions |
| AU2009236960A1 (en) | 2008-04-16 | 2009-10-22 | The Chemo-Sero-Therapeutic Research Institute | Method of producing thrombin-immobilized bioabsorbable sheet preparation |
| UA111342C2 (uk) | 2010-10-29 | 2016-04-25 | Троікаа Фармасьютікалс Лімітед | Назальні композиції вітаміну b12 |
| EP4085899A1 (en) | 2011-06-14 | 2022-11-09 | Neurelis, Inc. | Administration of benzodiazepine |
| US10485798B2 (en) | 2012-08-22 | 2019-11-26 | Aptapharma Inc. | Methylnaltrexone nasal formulations, methods of making, and use thereof |
| US20140171458A1 (en) | 2012-12-13 | 2014-06-19 | 3B Pharmaceuticals, Inc. | Intranasal naltrexone |
| DE202013105715U1 (de) | 2013-08-22 | 2014-02-19 | Sipnose Ltd. | Vorrichtung zur Abgabe einer vorbestimmten Menge einer Substanz an eine natürliche Öffnung des Körpers |
| WO2015054730A1 (en) | 2013-10-14 | 2015-04-23 | Palmaya Pty Ltd | Compositions and methods of administering same |
| WO2015095389A1 (en) | 2013-12-18 | 2015-06-25 | Aegis Therapeutics, Llc | Compositions for drug administration |
| US9192570B2 (en) * | 2013-12-20 | 2015-11-24 | AntiOP, Inc. | Intranasal naloxone compositions and methods of making and using same |
| US10085937B2 (en) | 2014-03-14 | 2018-10-02 | Adapt Pharma Limited | Nasal drug products and methods of their use |
| US9480644B2 (en) | 2014-03-14 | 2016-11-01 | Opiant Pharmaceuticals, Inc. | Nasal drug products and methods of their use |
| US9561177B2 (en) | 2014-03-14 | 2017-02-07 | Adapt Pharma Limited | Nasal drug products and methods of their use |
| HK1231370A1 (zh) | 2014-03-14 | 2017-12-22 | 欧皮安特制药有限公司 | 鼻用药物产品及其使用方法 |
| US20160008277A1 (en) | 2014-07-09 | 2016-01-14 | Lightlake Therapeutics Inc. | Co-packaged drug products |
| US9517307B2 (en) | 2014-07-18 | 2016-12-13 | Kaleo, Inc. | Devices and methods for delivering opioid antagonists including formulations for naloxone |
| KR102453781B1 (ko) * | 2016-06-24 | 2022-10-12 | 오피언트 파마슈티컬스, 인코퍼레이티드 | 알코올 사용 장애의 치료용 조성물, 장치 및 방법 |
| WO2018089709A1 (en) | 2016-11-09 | 2018-05-17 | Opiant Pharmaceuticals, Inc. | Compositions, devices, and methods for the treatment of opioid-receptor-mediated conditions |
| CN110139651A (zh) | 2016-11-18 | 2019-08-16 | 欧邦特制药公司 | 用于治疗阿片样物质过量的组合物和方法 |
| CN106361700A (zh) | 2016-11-25 | 2017-02-01 | 威海恒基伟业信息科技发展有限公司 | 盐酸纳美芬鼻腔给药制剂 |
| CA3100834A1 (en) | 2018-05-17 | 2019-11-21 | Aegis Therapeutics Llc | Formulations and methods for the prevention of opioid overdose |
| CA3119031A1 (en) | 2018-11-07 | 2020-05-14 | Opiant Pharmaceuticals, Inc. | Methods, parenteral pharmaceutical formulations, and devices for the prevention of opioid overdose |
| US20200390691A1 (en) | 2018-12-20 | 2020-12-17 | Aegis Therapeutics, Inc. | Compositions, devices, and methods for the treatment of overdose and reward-based disorders |
| AU2019403368A1 (en) | 2018-12-20 | 2021-07-29 | Aegis Therapeutics, Llc | Compositions, devices, and methods for the treatment of overdose and reward-based disorders |
-
2017
- 2017-11-09 CN CN201780081719.4A patent/CN110139651A/zh active Pending
- 2017-11-09 IL IL266674A patent/IL266674B2/en unknown
- 2017-11-09 IL IL312012A patent/IL312012A/en unknown
- 2017-11-09 JP JP2019526565A patent/JP7312698B2/ja active Active
- 2017-11-09 CA CA3044221A patent/CA3044221A1/en active Pending
- 2017-11-09 WO PCT/US2017/060964 patent/WO2018093666A1/en not_active Ceased
- 2017-11-09 US US16/461,354 patent/US11458091B2/en active Active
- 2017-11-09 RU RU2019118465A patent/RU2769397C2/ru active
- 2017-11-09 AU AU2017360910A patent/AU2017360910B2/en active Active
- 2017-11-09 EP EP17871739.3A patent/EP3541386A4/en active Pending
-
2022
- 2022-08-04 US US17/881,191 patent/US20220387306A1/en not_active Abandoned
-
2023
- 2023-07-10 JP JP2023112864A patent/JP7730443B2/ja active Active
-
2024
- 2024-02-19 AU AU2024201047A patent/AU2024201047A1/en active Pending
- 2024-06-25 US US18/753,188 patent/US20250127712A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019534315A5 (https=) | ||
| RU2019118465A (ru) | Композиции и способы лечения передозировки опиоидами | |
| US20210077382A1 (en) | Compositions, devices, and methods for the treatment of opioid-receptor-mediated conditions | |
| US9629965B2 (en) | Nasal drug products and methods of their use | |
| JP2021046408A (ja) | 経鼻薬物製品およびその使用方法 | |
| AU2017281941A1 (en) | Compositions, devices, and methods for the treatment of alcohol use disorder | |
| CN102905689A (zh) | 包含低剂量纳曲酮的液体鼻喷雾 | |
| US20250319081A1 (en) | Compositions, Devices, and Methods for Treating or Preventing Headaches | |
| AU2017379247A1 (en) | Pharmaceutical dosage forms containing TASK-1 and TASK-3 channel inhibitors, and the use of same in breathing disorder therapy | |
| US12514854B2 (en) | Drug products for intranasal administration and uses thereof | |
| JP2020502215A (ja) | Ｔａｓｋ−１およびｔａｓｋ−３チャネル阻害剤を含む医薬剤形、ならびに呼吸障害療法におけるその使用 | |
| CN108472375A (zh) | 中重度流感的治疗方法 | |
| JP5828007B2 (ja) | 局所投与型の嚥下障害改善用医薬品 | |
| WO2025255116A1 (en) | Methods of treatment for opioid-induced ventilatory depression and muscle rigidity | |
| US20240408003A1 (en) | Compositions, devices and methods for the treatment of alcohol use disorder | |
| EP2061497A1 (en) | Compositions and methods for treatment of chronic fatigue syndrome and neurodegenerative diseases | |
| WO2014199486A1 (ja) | 嚥下障害改善用医薬品 |